Table 2.

The most cited studies about Omalizumab and a better antiviral response (increasing IFN- α production)

STUDY	VIRUS	OUTCOME
Busse (2011)	influenza virus, rhinovirus	“Omalizumab significantly reduced the proportion of participants who had one or more exacerbations”
Durrani SR (2012)	rhinovirus, RV-16	“Innate immune responses reduced by the high-affinity IgE receptor in allergic asthmatic children; after FcεRI cross-linking, allergic asthmatic children had significantly lower HRV-induced IFN responses”
Teach SJ (2015)	rhinovirus RV-16	“Omalizumab improved IFN-α responses to rhinovirus, and within the omalizumab group, greater IFN-α increases were associated with fewer exacerbations” (PROSE STUDY)
Saini SS (2015)	upper airway infections	“Targeting IgE with Omalizumab in asthma or chronic spontaneous urticaria patients did not increase upper airway infections”
Kantor DB (2016)	rhinovirus	“Omalizumab reduces acute severity of rhinovirus-triggered asthma exacerbation”
Esquivel A (2017)	rhinovirus	“Direct evidence that blocking IgE decreases susceptibility to RV infections and related-illness”
Edwards MR (2017)	viral infections	“Anti-T2 biologics are particularly successful in controlling asthma exacerbations”
Gill MA (2018)	rhinovirus- and influenza	“Omalizumab enhanced plasmacytoid dendritic cell antiviral responses”
Jartti T (2019)	rhinovirus	“Pre-seasonal treatment with Omalizumab has been shown to eliminate the seasonal peaks in asthma exacerbations, most of which are associated with RV infection”
Heymann PW (2020)	rhinovirus, RV-16	“The effect of administering Omalizumab on the response to rhinovirus was most pronounced during the early/innate phase of the infection”
Altman MC (2020)	viral infection	“There are emerging therapeutic options to decrease severity of wheezing exacerbations caused by respiratory viral infections”